ArticleLiver cancer2025

Higher Risk of Proteinuria with Atezolizumab plus Bevacizumab than Lenvatinib in First-Line Systemic Treatment for Hepatocellular Carcinoma.

Jiwon Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.